AzTrials
AzTrials

AbdominoplastyNCT03940885

Erector Spinae Plane Block Versus Transversus Abdominis Plane Block in Abdominoplasty Surgery

A study testing Erector spinea plane block group and Transversus abdominis plane block in people with Abdominoplasty, run by Mansoura University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Abdominoplasty is one of the most popular body-contouring procedures. Patients that undergo body-contouring abdominoplasty usually have important analgesic requirements. Given the substantial incision and soft-tissue undermining associated with this procedure, postoperative pain is a concern for patients and surgeons. Read more about this study

Who is it for?
Ages 25 to 65 years
Conditions the study is for
Abdominoplasty
What is being tested?
Erector spinea plane block group and Transversus abdominis plane block
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
69 participants
Where
1 siteEgypt
Study dates
1 Apr 2019to Jun 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • American society of anesthesiologist grade I-II

Who cannot join

  • Patient refusal.
  • Local skin infection and sepsis at the site of the block.
  • Allergy to local anesthetic used.
  • Hematological diseases
  • Bleeding disease.
  • Coagulation abnormality.
  • Psychiatric disorders.

Trial locations and contacts

1 site in 1 country.

Mona A Hasheesh, MD contact

01223912912947

drmonahasheesh@hotmail.com

Hanaa M Elbendary, MD contact

00201005781768

hanaa_elbendary@yahoo.com

Egypt1 site, 1 recruiting
  • Hanaa M Elbendary

    Al Mansurah, DK, 050

    Hanaa M Elbendary, MD, 00201005781768 ext. 00201005781768, hanaa_elbendary@yahoo.com

    Mona A Hasheesh, MD, drmonahasheesh@hotmail.com

    Recruiting

Other trials in Egypt

About this study

Official title: Erector Spinae Plane Block: An Analgesic Technique as an Alternative to Transversus Abdominis Plane Block in Abdominoplasty Surgery

Abdominoplasty is one of the most popular body-contouring procedures. Patients that undergo body-contouring abdominoplasty usually have important analgesic requirements. Given the substantial incision and soft-tissue undermining associated with this procedure, postoperative pain is a concern for patients and surgeons. Previous studies have typically incorporated multiple nerve blocks to improve analgesia after abdominoplasty. Different anesthetic techniques have been developed to overcome this problem such as Epidural anesthesia, Transversus abdominis plane block either open technique or ultrasound-guided, Paravertebral block and Erector Spinea plane block. Improving postoperative pain control in this kind of surgery leads to earlier mobilization, shortened hospital stay, reduced hospital costs, and increased patient satisfaction.

The ultrasound-guided erector spinae plane (ESP) block is a recent block described for various surgeries for postoperative analgesia. It is reported that it have an analgesic effect on somatic and visceral pain by affecting the ventral rami and rami communicantes that include sympathetic nerve fibres, as LA spreads through the paravertebral space. When performed bilaterally it has been reported to be as effective as thoracic epidural analgesia.

Read more

The transversus abdominis plane (TAP) block is a technique of locoregional anesthesia that blocks the sensorial afferent nerves localized between the transversus abdominis muscle and the internal oblique muscle.

In this study, the analgesic efficacy and duration of ultrasound (US) guided Erector spinea plane block and Transversus abdominis plane block when Lidocaine HCL is added as an adjuvant to bupivacaine will be compared.

Read the detailed description

Sample size was calculated using Power Analysis and Sample Size software program (PASS) version 15.0.5 for windows (2017) using previous results with the mean opioid consumption in the first postoperative day as the primary outcome. Effect size of 0.5 (medium effect size) was calculated using the difference between the mean opioid consumption in TAB group (140 mg) and that in ESPB group (124.6 mg) with an estimated standard deviation of 30 in both groups. This study will add a control group in which only intravenous analgesics will be used; hence the aforementioned effect size was used for sample size calculation using a one-way ANOVA test. Sample sizes of 18 patients in each group are needed to achieve 90% power (1-β) to detect differences among the means using an F test with a 0.05 significance level (α). The size of the variation in the means is represented by the effect size f = σm / σ, which is 0.5. A 20% drop out is expected so the drop-out inflated sample size will be 23 patients in each group.

Conditions
Abdominoplasty
Being tested
Erector spinea plane block group, Transversus abdominis plane block, Control group

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Erector spinea plane block groupProcedure or surgery

    Which will receive ultrasound-guided erector spinea plane block bilaterally and the local anesthetic injected will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline

  • Transversus abdominis plane blockProcedure or surgery

    Which will receive ultrasound-guided Transversus Abdominis plane block bilaterally and the local anesthetic used will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline

  • Control groupProcedure or surgery

    this group will receive only standard general anesthesia

Study groups in NCT03940885
Study groupRoleWhat they receive
Erector spinea plane block groupActive comparatorthis group is planned for ultrasound-guided Transversus abdominis plane block
Receives: Procedure: Erector spinea plane block group
Transversus abdominis plane blockActive comparatorthis group is planned for ultrasound-guided Transversus abdominis plane block
Receives: Procedure: Transversus abdominis plane block
Control groupPlacebo comparatorstandard general anesthesia
Receives: Procedure: Control group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total opioid consumption

    cumulative consumption of rescue opioids during the first postoperative day

    Measured: For 24 hours after performing block

Secondary outcomes (7)
  1. Duration of analgesia

    the first time patient requests analgesia postoperatively

    Measured: for 24 hours after performing block

  2. Postoperative visual analogue score

    postoperative visual analogue score (VAS)which will be used to determine the postoperative pain levels in patients. ( 0 representing no pain and 10 is the worst imaginable pain) will be assessed at 2h, 4h,6h,12h,18h and 24h postoperative. Diclofenac75 mg IV and paracetamol 500 mg will be given to all patients in the three groups every 12 hours. If VAS is > 4 patient will receive pethidine 25 mg IV

    Measured: for 24 hours after performing block

  3. Cortisol level

    Cortisol level will be assayed in the serum

    Measured: For one hour after performing block

  4. Heart rate

    Changes in heart rate

    Measured: For 24 hours after surgery

  5. Mean arterial blood pressure

    Changes in mean arterial blood pressure

    Measured: For 24 hours after surgery

  6. Peripheral oxygen saturation

    Changes in peripheral oxygen saturation as measured with pulse oximetry

    Measured: For 24 hours after surgery

  7. Nausea and vomiting

    0: No nausea, 1: mild nausea, 2: moderate nausea, 3: severe nausea or vomiting

    Measured: For 24 hour after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 May 2019
  2. Study start1 Apr 2019
  3. Primary completionApr 2021 (estimated)
  4. Study completionJun 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
single-blind study
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
69 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03940885
Sponsor's protocol ID
MD.19.03.155
Status last verified
Sep 2020
First submitted
6 May 2019
Last updated
25 Sep 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Following completing recruiting and opening the dataset, the investigators would upload the raw data and results to the registry

Publications

  • Mankikar MG, Sardesai SP, Ghodki PS. Ultrasound-guided transversus abdominis plane block for post-operative analgesia in patients undergoing caesarean section. Indian J Anaesth. 2016 Apr;60(4):253-7. doi: 10.4103/0019-5049.179451.

    PubMed 27141108

Questions about this trial

What is this clinical trial studying?

A study testing Erector spinea plane block group and Transversus abdominis plane block in people with Abdominoplasty, run by Mansoura University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 25 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mona A Hasheesh, MD (01223912912947, drmonahasheesh@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total opioid consumption (time frame: For 24 hours after performing block). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03940885, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in